Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIRSARC
2023-509489-39-00Phase 3Authorised
- Sponsor
- Institut Bergonié
- Start
- Feb 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of ifosfamide, dacarbazine and doxorubicin in soft tissue sarcoma (STS) (2 arms), sponsored by Institut Bergonié. Primary endpoint: Metastasis progression-free survival (M-PFS). Planned start Feb 2024; status: authorised.
02
Drugs
ifosfamidedacarbazinedoxorubicin
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on 2023-509489-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509489-39-00.